Elipartal, >= 98%( HPLC ), poudre

Code: e2031-10mg D2-231

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

NR2B selective NMDA glutamate receptor antagonist which appears to target the "polyamine site" on the NMDA receptor, setting it apart from other NR2B ...


 En savoir plus

Votre prix
$207.31 10MG
DEMANDER

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

NR2B selective NMDA glutamate receptor antagonist which appears to target the "polyamine site" on the NMDA receptor, setting it apart from other NR2B receptor antagonists. Possesses neuroprotective effects in models of ischemia, but prolongs the QT interval in patients; currently under investigation for acute and chronic pain.

Features and Benefits

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

10, 50 mg in glass bottle

assay≥98% (HPLC)
colorwhite to beige
formpowder
Gene Informationhuman ... GRIN2B(2904)rat ... Adra1a(29412)
InChI keyGGUSQTSTQSHJAH-UHFFFAOYSA-N
InChI1S/C20H23ClFNO/c21-18-5-3-17(4-6-18)20(24)14-23-11-9-16(10-12-23)13-15-1-7-19(22)8-2-15/h1-8,16,20,24H,9-14H2
originatorSanofi Aventis
SMILES stringOC(CN1CCC(CC1)Cc2ccc(F)cc2)c3ccc(Cl)cc3
solubilityDMSO: 5 mg/mL, clear, H2O: insoluble
storage temp.2-8°C
Cas Number119431-25-3
Ce produit répond aux critères suivants pour être admissible aux récompenses suivantes :



PROCEED TO CHECKOUT

HAVE AN ACCOUNT? LOGIN
GUEST CHECKOUT

Proceed as a guest. You will have the option to register to access exclusive pricing and stock availability features after checkout.